Pediatric Influenza: what you need to know about testing, treatment & prophylaxis

Jennifer Mullendore, MD, MSPH

Medical Director

Buncombe County Dept. of Health & Human Services

January 8, 2014




Learning Objectives

- Understand the basic epidemiology of pediatric influenza and influenza-associated pediatric deaths
- Identify signs/symptoms of pediatric influenza
- Understand the use and limitations of influenza testing
- Understand the use of antiviral medications for the treatment and prevention of pediatric influenza




UPDATE ON CURRENT FLU SEASON






Courtesy of Anita Valiani, NC DHHS





Courtesy of Anita Valiani, NC DHHS






For Mission Health System

Courtesy of Dr. David Buhner, PHE





Courtesy of Anita Valiani, NC DHHS





FLUVIEW

http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html



Influenza Positive Tests Reported to CDC, National Summary, 2013-14 Season, weeks ending Dec 08, 2013 - Dec 28, 2013
Reported by: U.S. WHO/NREVSS Collaborating Laboratories





Courtesy of Anita Valiani, NC DHHS



EPIDEMIOLOGY OF PEDIATRIC INFLUENZA



The Toll of Pediatric Influenza


 Average # of children < 5 years of age hospitalized each year for influenza complications = 20,000

Influenza-associated death


- Death resulting from a clinically compatible illness confirmed to be influenza through testing
- No period of complete recovery between illness & death

Physicians must report this to local health dept.





2012-13




Season	Total Deaths	Influenza A	Influenza B	Influenza A & B
2013-14*	6	5	0	1

Make Small CHOICES, expect BIG things.




Laboratory Confirmed Influenza-Associated Deaths Reported in North Carolina, by Age Group*




Courtesy of Anita Valiani, NC DHHS
















Who is at higher risk for complications from influenza?

- Children < 5 yo, but especially <2 yo
- Chronic lung diseases (e.g., asthma, CF)
- Chronic heart diseases (except HTN only)
- Chronic kidney disorders
- Chronic liver disorders
- Chronic **blood** disorders (e.g., sickle cell disease)
- Chronic metabolic disorders (e.g., diabetes, inherited metabolic disorders)
- Persons w/ immunosuppression (e.g., HIV, cancer, chronic steriods)
- Persons who are morbidly obese

- Chronic neurologic and neurodevelopmental conditions (d/o of brain, spinal cord, peripheral nerve, & muscle such as CP, epilepsy, stroke, intellectual disability, moderate to severe developmental delay, muscular dystrophy, or spinal cord injury)
- Persons < 19 yo on long-term aspirin therapy
- American Indians/Alaskan Natives
- Pregnant or post-partum (within 2 wks after delivery)
- Residents of chronic-care facilities









Signs/Symptoms of Influenza

- Abrupt onset of
 - Fever (commonly 100 to 102°F lasting 3-4 days)
 - Chills
 - Myalgia (often severe)
 - Headache
 - Fatigue/weakness (often extreme exhaustion)
 - Non-productive cough
 - Sore throat
 - Sneezing and/or nasal congestion
 - Nausea, vomiting, otitis media also seen in children
 - Young children <u>less</u> likely to have typical influenza symptoms (like fever & cough)



Basic Epidemiology of Influenza

- Incubation period: 1-4 days
- Contagious period:
 - Adults from 1 day before symptoms start and for
 5-10 days after illness begins
 - Children may be contagious several days before illness starts and for 10+ days after illness begins
- Illness course: 3-7 days if uncomplicated
 - Cough, malaise can last > 2 wks



Influenza Complications

- Influenza viral pneumonia
- Exacerbation of underlying medical conditions
- Secondary bacterial pneumonia, sinusitis, otitis media
- Co-infections with other viral or bacterial pathogens
- Respiratory failure
- Death



How distinguish flu from other respiratory pathogens?

- Difficult based only on signs/symptoms
- PPV of acute onset of cough & fever in areas with confirmed influenza virus circulation for labconfirmed influenza infection

Population	PPV
Generally healthy older adolescents & adults	79-88%
Children 5-12 years old	71-83%
Children < 5 years old	64%

From http://www.cdc.gov/flu/professionals/acip/clinical.htm



Bottom-line for who to suspect of having influenza

 The diagnosis of influenza illness should be considered in any patient with respiratory symptoms <u>OR</u> fever during flu season.

 Influenza surveillance information and diagnostic testing can help clinical judgment.

TESTING FOR INFLUENZA



Diagnostic Testing for Flu

- Tests do <u>NOT</u> need to be performed on all patients with s/sx of flu
 - Once flu activity documented in community (especially during periods of peak activity), a clinical dx can be made for outpatients
 - Tests are most useful when they are likely to give results that will help with dx and tx decisions
- 2. Samples should be collected within the first 4 days of illness
- 3. Follow manufacturer's instructions for testing



Figure 1: Guide for considering influenza virus diagnostic tests for individual patients when influenza viruses are circulating in the community¹



http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm



Diagnostic Testing for Influenza

Test method	Potential Uses	Test Time
Viral Culture	Often for surveillance purposes (for virus strain ID, sub-typing, assessment for antiviral resistance, etc.) or confirmatory testing	3-10 days
Rapid Influenza Diagnostic Tests	Commonly for outpatient testing; can determine type	<15 minutes
RT-PCR	Used in-house at Mission; able to subtype; preferred for those w/exposure to animals/suspected to have novel influenza infection	1-6 hrs (longer if specimen has to be sent to outside lab)
Immunofluorescence (Direct or Indirect Antibody Staining)	Used for Mission's in-house "Viral Respiratory Panel" which tests for Influenza A & B, RSV, adenovirus, parainfluenzae types 1-3	1-4 hrs



Rapid Influenza Diagnostic Tests (RIDTs)

- Immunoassays that ID influenza A and B antigens in respiratory specimen
 - Some can distinguish between types A & B
- Qualitative (+/-)
- Results within 15 minutes
- Sensitivity 40-70%
- Specificity >90%



Use of RIDTs in Clinical Decisionmaking

False negative results more common than false positive results, especially during peak flu activity.

- ➤ Negative results do NOT rule out influenza infection in someone with s/sx suggestive of flu.
- > Do NOT withhold antiviral tx from patients with suspected flu, even if negative RIDT.

False + results can also occur, especially during times when flu activity is low.




Factors That Influence RIDT Accuracy

- 1. Clinical s/sx of influenza
- 2. Prevalence of influenza activity in population tested
- 3. Time from illness onset to specimen collection
- 4. Type of specimen collected
- **5.** Accuracy of test vs. "gold standard"
 - Sensitivity & specificity



Figure 3: Algorithm to assist in the interpretation of RIDT results and clinical decision-making during periods when influenza viruses are circulating in the community¹



http://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm



When to Consider Further Influenza Testing beyond RIDT

- Negative RIDT when high community flu activity & laboratory-confirmed influenza dx is desired
- + RIDT when low community flu activity & a false + is a possibility
- Recent close exposure to pigs, poultry or other animals & novel influenza A infection is possible



Hospitalized Patients

- 1. Test for flu if suspect flu
 - Immunofluorescence, RT-PCR or viral culture
- 2. Start empiric antiviral tx ASAP
 - > Do **NOT** wait for test results
 - > Do **NOT** stop antiviral tx if negative RIDT
- 3. Implement infection control measures upon admission (again, even if negative RIDT)
- 4. Consider testing specimens from different respiratory sites (e.g., upper & lower respiratory tract) and/or on > 1 day



ANTIVIRALS FOR TREATMENT & PROPHYLAXIS



Antivirals Recommended for Treatment & Chemoprophylaxis of Influenza A & B

Antiviral	Use	FDA Approved for Ages	Not Recom- mended for Use in	Adverse Events
Oseltamivir	Treatment	≥ 2 wks	n/a	Nausea, vomiting (may be less severe if taken w/ food)
(oral suspension or capsules)	Chemo- prophylaxis	<u>≥</u> 1 yr	n/a	
Zanamivir (inhaled powder)	Treatment	≥ 7 yrs	People w/ underlying respiratory disease (e.g., asthma)	Diarrhea, nausea, sinusitis, nasal s/sxs, cough, headache, dizziness, ENT infections; Allergic reactions: oropharyngeal or facial edema
	Chemo- prophylaxis	<u>></u> 5 yrs		

Adapted from http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (cited Jan. 5, 2014; page last updated Oct. 1, 2013)

When to Give Influenza Antivirals

- ➤ ASAP for anyone with *suspected or confirmed* influenza who:
 - is hospitalized;
 - has severe, complicated or progressive illness; OR
 - is at higher risk for severe illness/complications

- > Ideally start tx within 48 hrs of illness onset
 - May still be beneficial when started after 48 hours



Antiviral Treatment of Patients NOT at High-Risk

- Antiviral tx can be considered for suspected or confirmed influenza in previously healthy, symptomatic outpatients not at high risk
 - Use clinical judgment
 - If tx can be initiated within 48 hours of illness onset



Key Messages on Treatment with Antivirals

- ➤ Focus use on those with severe illness or who are at higher risk for severe disease
- > Do NOT wait on test results
- > Start ASAP after illness onset
- > Do NOT withhold antiviral tx from patients with suspected flu, even if negative RIDT.
- ➤ H/o influenza vaccination does NOT rule out influenza infection give antivirals if indicated



Benefits of Influenza Antiviral Treatment

- Treatment with antivirals may:
 - **➤** Shorten duration of fever & other symptoms
 - > Reduce risk of complications from flu
 - > Shorten duration of hospitalization

 Clinical benefit is greatest when antivirals started within 48 hrs of illness onset



Recommended Dosage & Duration of TREATMENT for Influenza Antivirals

Antiviral	Dose	Duration of treatment	
Oseltamivir	If < 1 yr old: 3 mg/kg/dose BID (FDA-approved if \geq 2 wks old; requires a different dispenser than what is co- packaged with medicine)	•Recommended for 5 days.	
	If ≥1 yr old & weigh < 15 kg: 30 mg BID	•Longer treatment courses can be	
	If >1 yr old & weigh > 15-23 kg: 45 mg BID	considered for	
	If ≥ 1 yr old & weigh > 23-40 kg: 60 mg BID	patients who remain	
	If ≥1 yr old & weigh > 40 kg: 75 mg BID	severely ill after 5	
Zanamivir	If ≥ 7 yr old: 10 mg (2 inhalations) BID (Not FDA-approved for use in children younger than 7 years of age)	days of treatment.	

Taken from table at http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Cited Jan. 5, 2014; page last updated Oct. 1, 2013)

Chemoprophylaxis for Influenza

1. Annual influenza vaccination

- 2. Antiviral medications
 - 70-90% effective at preventing flu
 - NOT recommended if > 48 hrs since last exposure
 - CDC does <u>NOT</u> recommend widespread or routine use of antivirals for chemoprophylaxis
 - Need to seek medical care if develop s/sxs of influenza

**Alternative = close monitoring/early initiation of antiviral tx



Recommendations for Antiviral Chemoprophylaxis of Children

- To control outbreaks among high-risk children in institutional settings
- High-risk children who are close contacts of suspected or confirmed cases (regardless of vaccination status)
- High-risk children for whom vaccination is contraindicated or during 2 wks after vaccination (during outbreak)



Recommended Dosage of Influenza Antivirals for CHEMOPROPHYLAXIS in Children

Antiviral	Dose	Duration	
Oseltamivir	If < 3 months of age, use not recommended unless situation judged critical. (**Not FDA-approved)	•Recommended to be continued	
	If \geq 3 months of age & < 1 year old: 3 mg/kg/dose once daily (**Not FDA-approved)	until 7 days after last	
	If ≥ 1 year old & weigh ≤ 15 kg: 30 mg daily If ≥ 1 year old & weigh > 15 - 23 kg: 45 mg daily	(CDC has	
	If > 1 year old & weigh > 23 - 40 kg: 60 mg daily	additional	
	If \geq 1 year old & weigh > 40 kg: 75mg daily	guidance if outbreak in long-	
Zanamivir	If ≥ 5 years old: 10 mg (2 inhalations) once daily (Not FDA-approved for use in children younger than 5 years old)	term care facility or hospital)	

Taken from table at http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Cited Jan. 5, 2014; page last updated Oct. 1, 2013)

CONTROL MEASURES







Resources

- CDC Information for Health Professionals
 - http://www.cdc.gov/flu/professionals/index.htm
- NC Division of Public Health Flu info for providers
 - http://www.flu.nc.gov/providers/
- AAP Recommendations for Prevention and Control of Influenza in Children, 2013–2014
 - http://pediatrics.aappublications.org/content/early/2013/08/28/peds.2013-2377
- The Joint Commission videos demonstrating specimen collection
 - http://www.youtube.com/watch?v=hXohAo1d6tk
- The Joint Commission -- Strategies for Improving Rapid Influenza Testing in Ambulatory Settings (CE available)
 - http://www.jointcommission.org/siras.aspx
- Buncombe County Health and Human Services flu posters in English/Spanish/Russian
 - http://buncombecounty.org/flu

